Author

Thomas Doerr

Observed name: T Doerr

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5039095946

Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).

2025 · Muhamed Baljevic, Peter M. Voorhees, et al. · Journal of Clinical Oncology · 6

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

2024 · Hira Mian, Muhamed Baljevic, et al. · Blood · 5

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

2022 · Kalatu R. Davies, Rajesh Kamalakar, et al. · Blood · 3

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

2022 · Jeff P. Sharman, Ralph V. Boccia, et al. · Blood · 3

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.

2024 · David Jacob Andorsky, Ralph V. Boccia, et al. · Journal of Clinical Oncology · 2

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

2024 · Catherine Thieblemont, Yasmin H. Karimi, et al. · Blood · 1

PA-181 Etentamig in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-Cell Maturation Antigen (BCMA)-Targeted Therapy

2026 · Saurabh Chhabra, Emma Searle, et al. · Clinical Lymphoma Myeloma & Leukemia

Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.

2026 · Saurabh Chhabra, Emma Searle, et al. · Journal of Clinical Oncology

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6

2026 · David Andorsky, Adelba Torres Lopez, et al. · Clinical Lymphoma Myeloma & Leukemia

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

2025 · Aarif Ahsan, Adam Luo, et al. · Blood

Infection Rate Profile of Etentamig Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

2025 · Cesar Rodriguez Valdes, Eben Lichtman, et al. · Clinical Lymphoma Myeloma & Leukemia

EE458 Health Care Resource Utilization and Costs of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Claims Database Analysis in the US

2022 · K Davies, R Kamalakar, et al. · Value in Health

Works count: 12

Citation count: 20

H-index: 3

I10-index: